title: rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study.
abstract: To decrease red blood cell (RBC) transfusion requirements during high-dose therapy (HDT) for hematological malignancies, we conducted a pilot study to assess the effect of recombinant human erythropoietin (rHuEpo) given during chemotherapy before HDT and autologous peripheral stem-cell transplantation (APSCT). The transfusion histories of 15 HDT and APSCT for hematological disease performed in 11 consecutive patients who received rHuEpo (10 000 U subcutaneously three times/week) were compared to those of 22 HDT and ASCT performed in 17 consecutive historical controls matched for hematological parameters. rHuEpo increased the hemoglobin (Hb) level from 10.3+/-2.3 g/dl at diagnosis to 12.9+/-2.2 g/dl at the time of HDT in 11 patients; no major adverse effects occurred. Compared to historical controls (95%, 21/22), RBC transfusion requirements were significantly lower for rHuEpo recipients (26%, 4/15) (P=0.00001) and rHuEpo responders (15%, 2/13) (P=0.000002). After HDT and APSCT, fewer RBC transfusions were needed: 3.3, 1.2 and 0.3 RBC units for controls, rHuEpo recipients and rHuEpo responders, respectively (P=0.006 and 0.00002). Therefore, rHuEpo should be administered before, and not after HDT and APSCT, to lower RBC transfusion requirements after HDT and APSCT.
authors.affiliation: Blood Disease Department, University Hospital, Angers, France.
authors.forename: M
authors.initials: M
authors.lastname: Hunault-Berger
authors.forename: A
authors.initials: A
authors.lastname: Tanguy-Schmidt
authors.forename: P
authors.initials: P
authors.lastname: Rachieru
authors.forename: V
authors.initials: V
authors.lastname: Lévy
authors.forename: M
authors.initials: M
authors.lastname: Truchan-Graczyk
authors.forename: S
authors.initials: S
authors.lastname: Francois
authors.forename: M
authors.initials: M
authors.lastname: Gardembas-Pain
authors.forename: M
authors.initials: M
authors.lastname: Dib
authors.forename: C
authors.initials: C
authors.lastname: Foussard
authors.forename: N
authors.initials: N
authors.lastname: Piard
authors.forename: A
authors.initials: A
authors.lastname: Godon
authors.forename: P
authors.initials: P
authors.lastname: Solal-Celigny
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
mesh_terms: D000328:Adult; D000368:Aged; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000097:blood / Q000628:therapy*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D010865:Pilot Projects; D011994:Recombinant Proteins; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin